Payment overview · 2025
General Payments
$15,623.79
111 reported records · 14 companies
Healthcare provider profile · identity verified
George M Bright, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adolescent Medicine · MIDLOTHIAN, VA · NPI 1235181702
Verified facts
What the public records show
CMS Open Payments records show George M Bright, M.D. received $15,623.79 in general payments during 2025 across 111 reported records.
Tris Pharma Inc accounted for 62.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adzenys Xr-Odt, Jornay Pm, Trintellix.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Jornay PM as an associated drug or biological on 46719 records involving 16334 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jornay Pm by this doctor in 2024.
Neos Therapeutics, LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adzenys XR-ODT as an associated drug or biological on 3241 records involving 1599 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Adzenys Xr-Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $9,728.96 | 62.3% | 25 | 2025 |
| AYTU BioPharma, Inc. | Unresolved — no canonical attribution shown | $2,250.00 | 14.4% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $1,462.52 | 9.4% | 15 | 2025 |
| Eton Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 6.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $396.59 | 2.5% | 31 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $276.09 | 1.8% | 12 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $185.07 | 1.2% | 7 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.91 | 1.0% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $65.36 | 0.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.01 | 0.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.62 | 0.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.69 | 0.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.53 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.44 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,300.00 | 10 |
| Food and Beverage | $2,023.79 | 98 |
| Consulting Fee | $1,500.00 | 2 |
| Honoraria | $800.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $9,605.42 | 20 | 2025 |
Source payment records
|
|||||
| Quillichew ER Normalized: quillichew er |
Drug | Tris Pharma Inc | $6,400.00 | 8 | 2025 |
Source payment records
|
|||||
| Quillivant Normalized: quillivant |
Drug | Tris Pharma Inc | $6,400.00 | 8 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $5,723.54 | 12 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | AYTU BioPharma, Inc., Neos Therapeutics, LP | $3,415.12 | 15 | 2025 |
Source payment records
|
|||||
| Cotempla XR-ODT Normalized: cotempla xr odt |
Drug | AYTU BioPharma, Inc. | $2,250.00 | 2 | 2025 |
Source payment records
|
|||||
| ALKINDI Normalized: alkindi |
Drug | Eton Pharmaceuticals, Inc. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| INCRELEX Normalized: increlex |
Drug | Eton Pharmaceuticals, Inc. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| KHINDIVI Normalized: khindivi |
Drug | Eton Pharmaceuticals, Inc. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $396.59 | 31 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $318.67 | 14 | 2025 |
Source payment records
|
|||||
| EXXUA Normalized: exxua |
Drug | Neos Therapeutics, LP | $297.40 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $185.07 | 7 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $152.91 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adzenys XR-ODT adzenys xr odt |
2025 | Adzenys Xr-Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Jornay PM jornay pm |
2025 | Jornay Pm | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Jornay PM open payments reported associated product |
CMS Open Payments — General Payments 46719 supporting records · 16334 recipient NPIs · example record 1224105018 |
Jornay Pm · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Neos Therapeutics, LP Exact reporting entity; no affiliate inference |
2025 | Adzenys XR-ODT open payments reported associated product |
CMS Open Payments — General Payments 3241 supporting records · 1599 recipient NPIs · example record 1206088044 |
Adzenys Xr-Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 110 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 73 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 66 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 26 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Jornay Pm | Methylphenidate Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Adzenys Xr-Odt | Amphetamine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,623.79 · 111 records | Tris Pharma Inc | ALKINDI, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, Cotempla XR-ODT, Dyanavel XR, EXXUA, INCRELEX, Jornay PM, KHINDIVI, Onyda XR, Qelbree, Quillichew ER, Quillivant, REXULTI, SUBLOCADE, TRINTELLIX, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adzenys Xr-Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Collegium Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error